AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.61% | 9.93% | 8.63% | 13.52% | 15.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.61% | 9.93% | 8.63% | 13.52% | 15.00% |
| Cost of Revenue | 12.21% | 14.98% | 10.77% | 1.05% | 16.03% |
| Gross Profit | 7.84% | 8.85% | 8.16% | 16.38% | 14.78% |
| SG&A Expenses | 9.64% | 5.65% | 3.57% | 2.87% | 5.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -81.48% | -58.82% | 14.74% | -13.96% | 29.21% |
| Total Operating Expenses | 9.83% | 9.84% | 8.43% | 6.24% | 11.43% |
| Operating Income | 4.98% | 10.18% | 9.25% | 39.19% | 27.14% |
| Income Before Tax | 25.57% | 38.96% | 42.70% | 44.40% | 29.40% |
| Income Tax Expenses | 23.94% | 66.84% | 31.45% | 43.11% | 32.28% |
| Earnings from Continuing Operations | 25.91% | 33.55% | 45.33% | 44.68% | 28.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 60.00% | -33.33% | 0.00% | -40.00% |
| Net Income | 25.93% | 33.67% | 45.34% | 44.71% | 28.80% |
| EBIT | 4.98% | 10.18% | 9.25% | 39.19% | 27.14% |
| EBITDA | 6.30% | 9.78% | 8.80% | 22.34% | 19.95% |
| EPS Basic | 25.90% | 33.64% | 45.25% | 44.61% | 28.72% |
| Normalized Basic EPS | 4.79% | 10.20% | 9.93% | 43.26% | 30.66% |
| EPS Diluted | 25.78% | 33.57% | 45.29% | 44.97% | 28.81% |
| Normalized Diluted EPS | 4.81% | 10.24% | 10.00% | 43.33% | 30.69% |
| Average Basic Shares Outstanding | 0.03% | 0.03% | 0.06% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | 0.02% | -0.02% | 0.00% | 0.00% | 0.05% |
| Dividend Per Share | -30.33% | 3.23% | 3.23% | 5.39% | 5.39% |
| Payout Ratio | -0.21% | -0.26% | -0.26% | -0.26% | -0.14% |